Drug Profile
Gisadenafil
Alternative Names: UK-369,003Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Erectile dysfunction therapies; Small molecules
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia; Chronic obstructive pulmonary disease; Erectile dysfunction; Overactive bladder
Most Recent Events
- 27 Aug 2007 No development reported - Phase-I/II for Chronic obstructive pulmonary disease in Argentina (PO)
- 27 Aug 2007 No development reported - Phase-I/II for Chronic obstructive pulmonary disease in Australia (PO)
- 27 Aug 2007 No development reported - Phase-I/II for Chronic obstructive pulmonary disease in Germany (PO)